Low‑cost cfDNA methylation test emerges

Low-cost cfDNA methylation test emerges A UCLA-led research team has unveiled MethylScan, a blood test designed to read disease signals from fragments of DNA already circulating in the bloodstream. In an early study published April 6, 2026 in the *Proceedings of the National Academy of Sciences*, the method detected multiple cancers and several non-cancer conditions from a single blood sample. (newsroom.ucla.edu) The idea starts with cell-free DNA, which is DNA shed into blood when cells die. UCLA researchers note that roughly 50 billion to 70 billion cells die in the body each day, and their DNA enters circulation, creating a constantly updated molecular snapshot of what is happening across organs. (newsroom.ucla.edu) That makes blood attractive for screening, but there is a catch: most of the DNA fragments in plasma do not come from tumors or injured organs. According to UCLA, about 80% to 90% of cell-free DNA in blood comes from normal blood cells, which creates background noise and makes rare disease signals harder and more expensive to detect. (eurekalert.org) Most existing liquid-biopsy tests look for mutations, meaning changes in DNA sequence. MethylScan instead looks for DNA methylation, a layer of chemical tagging on DNA that helps regulate gene activity and often differs by tissue type, so it can carry clues about both where DNA came from and whether that tissue is healthy or diseased. (newsroom.ucla.edu) That distinction matters because methylation-based testing can, in principle, do more than ask whether tumor DNA is present. The PNAS paper says comprehensive methylation profiling can capture organ-specific signatures, opening the door to simultaneous detection of cancers, liver disease, and other organ abnormalities from the same sample. (pnas.org) The UCLA group says MethylScan was built specifically to lower cost. Instead of relying on broad, deep sequencing across the whole methylome, the assay uses a strategy to strip away much of the low-information background DNA from blood cells and enrich the fragments more likely to come from non-blood tissues. (eurekalert.org) GenomeWeb’s report on the study describes that workflow in more technical terms: MethylScan uses methylation-sensitive restriction enzyme digestion to cut and remove relatively hypomethylated background cell-free DNA, then uses hybridization capture to enrich hypermethylated DNA from non-blood tissues. In plain language, it is trying to throw out the loudest irrelevant signal before sequencing starts. (genomeweb.com) In the study cohort, the researchers tested the method in 1,061 individuals across several use cases. Those included multicancer detection in a general-population cohort, surveillance for liver cancer in high-risk people, classification of liver disease, and identification of organ abnormalities. (pnas.org) For multicancer detection, the reported performance was strong but clearly not perfect. In liver, lung, ovarian, and stomach cancers, MethylScan achieved an area under the receiver operating characteristic curve of 0.938, with 63.3% sensitivity at 98.0% specificity across all stages. For early-stage cancers, the area under the curve was 0.916 and sensitivity was 55.3% at the same specificity. (pnas.org) Those numbers suggest a test that is better at keeping false positives low than at finding every cancer case, especially in early disease. That tradeoff is common in screening development, and it means MethylScan should be viewed as a promising research-stage assay rather than a finished population-wide screening product. This interpretation is an inference from the reported sensitivity and specificity, not a claim made verbatim by the study authors. (pnas.org) The study also pushes beyond cancer. UCLA said the assay showed utility in distinguishing liver conditions and detecting organ abnormalities, which fits the broader promise of cell-free DNA methylation: the same blood draw may be able to reflect injury or disease in multiple tissues, not just tumors. (newsroom.ucla.edu) For pathology and cytology labs, that could shift where molecular testing fits into workflow. If methylation-based cell-free DNA assays become validated and reimbursed, labs that already coordinate fluid-based diagnostics and liquid-biopsy testing may need to triage more blood-based molecular screens, decide which positives need confirmatory tissue workup, and manage a wider mix of assay types. That is a workflow implication based on the study’s design and current liquid-biopsy practice, rather than a direct statement from UCLA. (newsroom.ucla.edu) There is also a competitive angle. Many commercial liquid-biopsy programs have focused on one cancer type, one recurrence setting, or one narrow set of mutations. UCLA’s framing is different: a single, lower-cost methylome test that could screen for several diseases at once by reading tissue-specific epigenetic patterns. (pnas.org) The biggest unanswered question is validation. The April 2026 paper shows encouraging early performance, but broader clinical adoption would still require larger prospective studies, clearer evidence of how results change patient care, and proof that the lower-cost workflow holds up outside the original research setting. (pnas.org) For now, MethylScan looks less like a replacement for biopsy and more like a new front-end filter: a blood test meant to flag who may need closer imaging, more specific molecular testing, or tissue diagnosis. If later studies confirm the UCLA results, methylation-based cell-free DNA testing could widen the role of blood-based screening in cancer detection and organ-disease monitoring. (newsroom.ucla.edu)